2022 年 9 巻 1 号 p. 27-32
Objective: This study was conducted to clarify the influence of Helicobacter pylori infection status and proton pump inhibitor (PPI) administration on the prevalence of gastric hyperplastic polyps (GHPs).
Methods: The study subjects comprised 3,590 individuals (2,318 males, 1,272 females; mean age 55.1±9.6 years) who underwent medical checkups and in whom H. pylori infection status had been determined. The presence of GHPs accompanied by fundic gland polyps (FGPs) and the degree of gastric mucosal atrophy were investigated endoscopically. The use of antisecretory drugs at the time of examination was also noted.
Results: Seventy-five (2.1%) subjects showed GHPs on endoscopy findings. The prevalence ratios of GHPs in H. pylori-negative, -positive, and post-eradicated subjects were 2.5%, 1.6%, and 1.7%, respectively (p=0.374). GHP prevalence was markedly different between patients with and without PPI administration (21.3% vs. 0.9%, p<0.001). Accompanied FGPs were more frequently observed in patients with GHPs. Multiple logistic regression analysis revealed that PPI usage, older age, and milder gastric mucosal atrophy were significant risk factors for the presence of GHPs, while H. pylori infection status was not a significant factor for their occurrence.
Conclusion: A high prevalence of GHPs was observed in cases of PPI administration irrespective of H. pylori infection status.
